Back

Predictors of cardiac resynchronized therapy response and maximum allowable medical treatment period in dilated cardiomyopathy with left bundle branch block

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - treatment 6 Cardiac Resynchronisation Therapy (CRT) HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Minjung Bak

Samsung Medical Center, Seoul (Korea (Republic of))

7 More presentations in this session

Presentation thumbnail
Identifying predictors of non-response to cardiac resynchronization therapy in heart failure patients
Doctor L. Pinheiro (Guimaraes, PT)
Abstract Slides Video
Presentation thumbnail
Cardiac resynchronisation therapy's response in patients with atrial fibrillation
Doctor A. Ferreira (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Longitudinal assessment of ventricular arrhythmia burden before and after left ventricular assist device implantation: implications for risk stratification and postoperative management
Professor M. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Incidence and predictors of heart failure hospitalization after left ventricular assist device insertion
Doctor M. Bak (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Free triiodothyronine/free thyroxine ratio as a predictor of mortality in LVAD recipients during 12 months of observations
Doctor S. Wisniowska-Smialek (Krakow, PL)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - treatment 6

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Cardiac resynchronization therapy - beyond ejection fraction
thumbnail
Congress Presentation
Identifying predictors of non-response to cardiac resynchronization therapy in heart failure patients
thumbnail
Congress Presentation
Could ischemic etiology condemn patients to 'non-response' in cardiac resynchronization therapy?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources